Skip to content

The Effectiveness of Pasteurized Goat Milk in the Treatment of Childhood Oral Ulcer Diseases

Phase 1 1 Study Assesing the Benefit of Pasteurized Goat Milk in Reducing Disease Severity of Young Children With Oral Ulcer Diseases

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00333749
Enrollment
65
Registered
2006-06-06
Start date
2006-01-31
Completion date
2007-12-31
Last updated
2009-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Ulcer

Keywords

children

Brief summary

Children with acute diseases with oral ulcers (not included PRESENTATIONS OF SLE, IBD or IMMUNOCOMPRMIZED STATES)will receive several doses (drinking or mouth rinsing) of either pasteurized goat milk or cow milk. Children will than be followed for length of the disease - signs and symptoms.

Detailed description

A prospective randomized controlled study that will include 110 previously health 6months - 5 years children (55 in each group) with acute oral ulcer disease (\< 48 hours). Children will receive several doses (drinking or mouth rinsing) of either pasteurized goat milk or cow milk. Children will than be followed for length of the disease - sings and symptoms by questioner to parents, and physical examination by there physicians. .

Interventions

BIOLOGICALDrinking or rinsing the mouth 2-3 times for 1 day
BIOLOGICALPasturlized cow milk

Drinking or rinsing the mouth 2-3 times for one day.

Sponsors

HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Months to 5 Years
Healthy volunteers
Yes

Inclusion criteria

* Age \> 6 months or \< 5 years. * Acute (\< 48 hours) oral ulcer disease. * \> 5 ulcers. * Cooperative parents . * Signing inform consent.

Exclusion criteria

* All types of immunosuppression, IBD, SLE, recurrent oral ulcer, disease \> 48 hours, age , 6 \< months or \> 5 years.

Design outcomes

Primary

MeasureTime frame
Severity of disease3 years
Length of disease3 years

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026